FUNDC1 and prostate cancer: The results revealed that compared with that in the respective normal groups, FUNDC1 expression was higher in cancer groups, including breast, cervical, colorectal, lung, ovarian, pancreatic, and prostate cancers as well as leukemia and lymphoma.